Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Neurological biomarkers industry is projected to witness a CAGR of 10.9% during the period 2025-2034. This growth can be ...

Machine learning and artificial intelligence (AI) techniques and analysis of large datasets have helped University of ...

Using data collected from Fitbit smartwatches and fed to an AI model, a team was able to unearth links between genetic ...

Women with amnestic mild cognitive impairment and early Alzheimer’s disease had lower levels of acetyl-L-carnitine and its ...

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque ...

Understanding and predicting individual responses to common stressors is essential for optimising performance in high-stress ...

By studying biomarkers known to be involved in gastrointestinal cancers, researchers at the Johns Hopkins Kimmel Cancer ...

Ajay Goel, PhD, AGAF, discusses how the development and validation of novel non-invasive biomarkers can improve early detection and ultimately impact patient outcomes for patients.

The "Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region" report has been added to ...

Neurological biomarkers market size was valued at USD 9.5 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 10.9% between 2025 and 2034. The rising prevalence of ...